Publication: 2600

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 35 (19) 2184-2192
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
2606  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA016359, U10CA016450, U10CA021060, U10CA031983, U10CA037347, U10CA041287, U10CA047559, U10CA059518, U10CA077440, U10CA077658, U10CA180790, U10CA180833, U10CA180838, U10CA180850, U10CA180866, U10CA180870 , U10 CA077658, U10 CA031946, U10 CA033601, U10 CA021060, U10 CA180821, U10 CA059518, U10 CA077440, U10 CA180850, U10 CA041287, U10 CA047559, U10 CA180790, U10 CA180882, U10 CA180833, P30 CA016359, U10 CA180870, U10 CA180838, U10 CA180866  
Corr. Author:
 
Authors:
                                     
Networks:
CA043, KAISER, LAPS-IL036, LAPS-IL057, LAPS-MN026, LAPS-MO011, LAPS-NC010, MD015, NY175, OH008, VA002   
Study
CALGB-30801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Chemotherapy, ORIGINAL REPORTS, Thoracic Oncology